Inhibrx Biosciences, Inc. (INBX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$80.28-7.47%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · INBX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 896.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
INBX — credit agreement
Dated 2026-07-16
Entry Into a Material Definitive Agreement On July 15, 2026, Inhibrx Biosciences, Inc. (the “Company”), Oxford Finance LLC as collateral agent (“Collateral Agent”), and the other lenders party thereto (the “Lenders”), entered into a second amendment (the “Second Amendment”) to the Loan and Security Agreement dated as of January 13, 2025, as amended by the First Amendment dated March 18, 2026 (collectively, the “Oxford Loan Agreement”), pursuant to which the Lenders expanded the facility to an…
Why it matters: FDA feedback can set the path for ozekibart in colorectal cancer. A clear trial plan would mark progress.
Supportive ifThe company reports FDA agreement on a first-line CRC trial plan or a fourth-line path to faster approval.
Worry ifThe FDA does not support either path, or the company reports a need for major new studies before proceeding.
Why it matters: Phase 3 would test whether the Phase 2 benefit holds in a larger study. FDA alignment is a key step.
Supportive ifThe company reports FDA alignment on the trial plan and starts the Phase 3 portion of HexAgon.
Worry ifThe company delays the Phase 3 start or reports that FDA feedback requires a different trial plan.
Why it matters: The added patients will test the strong HPV+ response seen in a small group. This may support a faster approval path.
Watch forThe company enrolls about 50 more HPV+ OPSCC patients. It later reports response and safety results close to the earlier HPV+ signal.
Also watch forThe company reports slow or stopped enrollment. Or the larger group shows weaker responses or worse safety.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$240 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $649 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,939 loss on $10,000 · 49.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.